Home > Insider Trading > Filing (0001104659-24-070108)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1737953	Replimune Group Inc.	REPL	Biological Products, (No Disgnostic Substances) (2836)	822082553

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1956241	Konstantinos Xynos	C/O Replimune Group, Inc. 500 Unicorn Park Drive, Suite 303 Woburn MA 01801	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-06-07	15,881	$7.50	117,131	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof.